BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 11118036)

  • 1. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
    Urasaki Y; Takebayashi Y; Pommier Y
    Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
    Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
    Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
    Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
    Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
    Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
    Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.
    Lesueur-Ginot L; Demarquay D; Kiss R; Kasprzyk PG; Dassonneville L; Bailly C; Camara J; Lavergne O; Bigg DC
    Cancer Res; 1999 Jun; 59(12):2939-43. PubMed ID: 10383158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
    Liao Z; Robey RW; Guirouilh-Barbat J; To KK; Polgar O; Bates SE; Pommier Y
    Mol Pharmacol; 2008 Feb; 73(2):490-7. PubMed ID: 17984197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
    Lavergne O; Lesueur-Ginot L; Pla Rodas F; Kasprzyk PG; Pommier J; Demarquay D; Prévost G; Ulibarri G; Rolland A; Schiano-Liberatore AM; Harnett J; Pons D; Camara J; Bigg DC
    J Med Chem; 1998 Dec; 41(27):5410-9. PubMed ID: 9876111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
    Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
    Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamellarin D: a novel potent inhibitor of topoisomerase I.
    Facompré M; Tardy C; Bal-Mahieu C; Colson P; Perez C; Manzanares I; Cuevas C; Bailly C
    Cancer Res; 2003 Nov; 63(21):7392-9. PubMed ID: 14612538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
    Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
    Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Kasprzyk PG; Bailly C; Camara J; Bigg DC
    Anticancer Drugs; 2001 Jan; 12(1):9-19. PubMed ID: 11272292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.
    Lavergne O; Demarquay D; Bailly C; Lanco C; Rolland A; Huchet M; Coulomb H; Muller N; Baroggi N; Camara J; Le Breton C; Manginot E; Cazaux JB; Bigg DC
    J Med Chem; 2000 Jun; 43(11):2285-9. PubMed ID: 10841808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
    BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
    Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF
    Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
    Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
    Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
    Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
    Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
    Chen AY; Shih SJ; Garriques LN; Rothenberg ML; Hsiao M; Curran DP
    Mol Cancer Ther; 2005 Feb; 4(2):317-24. PubMed ID: 15713902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
    Tanizawa A; Pommier Y
    Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.